Abstract: An electronic apparatus includes an image acquisition unit configured to obtain a wide range image, an information acquisition unit configured to obtain attribute information including orientation information, and a control unit configured to control selection of any one of a plurality of processes based on a condition to display the wide range image, the plurality of processes including at least two of first to fourth processes, the first process providing a display in which a zenith and a yaw angle is corrected based on the orientation information, the second process providing a display in which the zenith is corrected based on the orientation information, the third process providing a display in which the yaw angle is corrected based on the orientation information, the fourth process providing a display in which neither the zenith nor the yaw angle of the wide range image is corrected.

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: An object of the present invention is to provide an antibody having significantly high affinity for VEGF compared to the prior art. The present invention provides a monoclonal antibody against VEGF, which binds to a vascular endothelial growth factor (VEGF) with a dissociation constant of 1×10?11 mol/L or less.

Abstract: An object of the present invention is to provide an antibody against VEGF that inhibits binding of a vascular endothelial growth factor (VEGF) to neuropilin-1 (NRP1). The present invention provides an antibody against VEGF that inhibits binding of VEGF to NRP1.

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Abstract: An electronic apparatus includes an image acquisition unit configured to obtain a wide range image, an information acquisition unit configured to obtain attribute information including orientation information, and a control unit configured to control selection of any one of a plurality of processes based on a condition to display the wide range image, the plurality of processes including at least two of first to fourth processes, the first process providing a display in which a zenith and a yaw angle is corrected based on the orientation information, the second process providing a display in which the zenith is corrected based on the orientation information, the third process providing a display in which the yaw angle is corrected based on the orientation information, the fourth process providing a display in which neither the zenith nor the yaw angle of the wide range image is corrected.

Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.

Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.

Abstract: The object of the present invention is to provide a reagent for detection or diagnosis of cancer. The present invention provides a reagent for detection or diagnosis of cancer, which comprises a monoclonal antibody against LGR6 or a fragment of the antibody.